Chinese maker of rapid diagnostic test kits, including COVID-19 antigen tests and other point-of-care immunoassays.
Chinese maker of rapid diagnostic test kits, including COVID-19 antigen tests and other point-of-care immunoassays.
Earns by selling test kits per unit, and COVID antigen kits carried the business during the pandemic, so sales fell sharply once mass testing ended. It now leans on its other infectious-disease tests and on overseas distributors to rebuild volume.
In one line: A Chinese Abbott/BinaxNOW-style rapid-test maker.
Moat: none. Rapid-test kits are largely commoditized with many domestic and global competitors.
Headquarters: Beijing, China · Employees: 571
Size Innovita Biological Technology (688253.SS) is a China Health Care company (Biotechnology) with a market value of $915M, the 2332nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥43.27 on 18 Nov 2026.
Performance Over six months the shares fell 27.9%, against -15.8% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 28.5% over the last twelve months (peer median +2.0%); the operating margin is 10.8% (peer median -25.0%).
Valuation It trades at 92.6× forward earnings against a peer median of 29.2× (2nd most expensive of 7).
Price implies For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is -17%, so the hurdle is +56 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.9 points above its cost of capital (9.9% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥308M | CN¥418M | CN¥618M | CN¥476M | CN¥439M |
| Revenue growth | — | -32% | +30% | +8% | — |
| Gross profit | CN¥237M | CN¥307M | CN¥481M | CN¥349M | CN¥254M |
| EBITDA | n/a | CN¥165M | CN¥264M | CN¥210M | CN¥120M |
| Net income | CN¥54.7M | CN¥144M | CN¥247M | CN¥174M | CN¥151M |
| Free cash flow | CN¥64.2M | CN¥183M | CN¥295M | CN¥261M | CN¥75.5M |
| Capital expenditure | CN¥16.0M | CN¥31.1M | CN¥36.2M | CN¥17.0M | CN¥57.7M |
| Total debt | CN¥6.84M | CN¥7.78M | CN¥5.77M | CN¥3.00M | CN¥25.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Innovita Biological Technology 688253.SS | $915M | -28% | -28% | 11% | 92.6× | 39.6% |
| Guangzhou Wondfo Biotech 300482.SZ | $1.05B | -18% | -24% | -2% | 28.4× | 14.3% |
| Abbott Laboratories ABT | $181B | +18% | +10% | 14% | 17.9× | 16.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688253.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.0% | -7.9% | 8th lowest of 21 |
| 6-month return | -27.9% | -15.8% | 6th lowest of 21 |
| Distance from 52-week high | -41.2% | -39.8% | 10th lowest of 21 |
| Revenue growth (TTM) | -28.5% | +2.0% | 3rd lowest of 17 |
| Operating margin | 10.8% | -25.0% | 4th highest of 17 |
| Forward P/E | 92.6× | 29.2× | 2nd most expensive of 7 |
| Growth the price implies (Req g, 7 yrs) | 39.6% | 7.8% | most demanding of 6 |
| Growth delivered (Del g) | -16.6% | +2.3% | 2nd lowest of 6 |
| Hurdle (Req g minus delivered) | +56.2 pp | +6.9 pp | most demanding of 6 |
| ROIC minus cost of capital | +5.9 pp | -11.2 pp | 2nd highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 92.6× | 39.6% | -16.6% |
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | n/a | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 41.5× | 6.1% | +4.4% |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 21.6× | 9.2% | +2.3% |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 143.0× | n/a | n/a |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 29.9× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | n/a | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | n/a | n/a | n/a |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | n/a | n/a | n/a |
| Alto Neuroscience ANRO | United States | $1.04B | +25% | n/a | n/a | n/a | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.05B | -18% | -24% | -2% | 28.4× | 14.3% | -5.8% |
| Daan Gene 002030.SZ | China | $1.05B | -17% | +1% | -81% | n/a | 4.8% | -32.3% |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.06B | -58% | -5% | -181% | n/a | n/a | n/a |
| Jade Biosciences JBIO | United States | $1.07B | -34% | n/a | n/a | n/a | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 19.4× | 7.8% | +2.4% |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | n/a | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | n/a | n/a | n/a |
| Vor Biopharma VOR | United States | $1.10B | +15% | n/a | n/a | n/a | n/a | n/a |